Theravance Biopharma - Company & Market Research Reports

Home /
Companies /
Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company that develops and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic. In addition, it has numerous product candidates, including Revefenacin (TD-4208), Axelopran, Velusetrag, TD-6450 and others. It also focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. Founded in 2013, it is based in George Town, the Cayman Islands.

REFINE BY

KEYWORD

Global Cyclophosphamide Drug Market Report and Forecast 2023-2031

 Report
April 2023
147 Pages
Global

From

€5693EUR$5,999USD£4,912GBP

Asthma And COPD Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029

 Report
November 2021
101 Pages
Global

From

€4270EUR$4,500USD£3,685GBP

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs: Global Strategic Business Report

 Report
November 2023
194 Pages
Global

From

€4697EUR$4,950USD£4,053GBP

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

 Report
September 2022
323 Pages
Global

From

€2372EUR$2,500USD£2,047GBP

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2023

 Report
August 2023
175 Pages
Global

From

€3796EUR$4,000USD£3,275GBP

€4745EUR$5,000USD£4,094GBP

NEED HELP FINDING THE RIGHT PRODUCT? Francesca will help you find what you are looking for.

Call: 1-800-526-8630 ASK A QUESTION REQUEST A CALL BACK

Global Antibiotics Market - Distribution by Type of Drug Class, Target Disease Indication, Type of Therapy (Monotherapies and Combination Therapies), Route of Administration and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

 Report
April 2023
175 Pages
Global

From

€5598EUR$5,899USD£4,831GBP

Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization. 2023 to 2027

 Report
November 2023
449 Pages
Global

From

€6638EUR$6,995USD£5,728GBP

Antibiotic Resistance Market Size, Share & Trends Analysis Report By Disease (cUTI, CDI), By Pathogen, By Drug Class (Oxazolidinones, Lipoglycopeptides), By Mechanism Of Action, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

 Report
May 2023
180 Pages
Global

From

€5646EUR$5,950USD£4,872GBP

Global Peptide Antibiotics Market Size, Share & Trends Analysis Report by Product Type, by Disease, by Route Of Administration (Oral, Injectable, Topical), by Distribution Channel, by Region, and Segment Forecasts, 2022-2030

 Report
July 2022
150 Pages
Global

From

€5646EUR$5,950USD£4,872GBP

Co-promotion and Co-marketing in Pharmaceuticals and Biotechnology 2016-2023

 Report
September 2023
200 Pages
Global

From

€3791EUR$3,995USD£3,271GBP

Novel Drug Reconstitution Systems Market by Type of Container, Fabrication Material, Physical State of Drug in Syringe and Cartridge, Physical State of Drug in Infusion Bag, Volume of Container, Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030

 Report
September 2021
325 Pages
Global

From

€4554EUR$4,799USD£3,930GBP

Global Peptide Antibiotics Market by Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics), Disease (Blood Stream Infections, HABP/VABP, Skin Infections), Route of Administration, Distribution Channel - Forecast 2023-2030

 Report
October 2023
182 Pages
Global

From

€3373EUR$3,554USD£2,910GBP

€3747EUR$3,949USD£3,234GBP

Global Methicillin-Resistant Staphylococcus Aureus Drugs Market by Agent Type (Ceftaroline, Daptomycin, Linezolid), Route of Administration (Oral, Parenteral), Sales Channel - Forecast 2023-2030

 Report
October 2023
191 Pages
Global

From

€3373EUR$3,554USD£2,910GBP

€3747EUR$3,949USD£3,234GBP

Antibiotic Resistance Market Report: Trends, Forecast and Competitive Analysis to 2030

 Report
October 2023
150 Pages
Global

From

€4602EUR$4,850USD£3,972GBP

Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

 Report
July 2022
714 Pages
Global

From

€2372EUR$2,500USD£2,047GBP

Celiac Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

 Report
June 2022
122 Pages
Global

From

€1898EUR$2,000USD£1,638GBP

Crohn's Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

 Report
April 2022
632 Pages
Global

From

€2372EUR$2,500USD£2,047GBP

MRSA Drugs - Global Strategic Business Report

 Report
November 2023
183 Pages
Global

From

€4697EUR$4,950USD£4,053GBP

Antibiotic Resistance Global Market Report 2023

 Report
September 2023
175 Pages
Global

From

€3796EUR$4,000USD£3,275GBP

€4745EUR$5,000USD£4,094GBP

Glycopeptide Antibiotics Global Market Report 2023

 Report
May 2023
250 Pages
Global

From

€3796EUR$4,000USD£3,275GBP

€4745EUR$5,000USD£4,094GBP

117 Results (Page 1 of 6)
- 1
- 2
- 3

ASK A QUESTION

An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net

*Required Information

Name*

Email Address* Please provide your business or academic email address.

Country*

Phone Number*

Your Question*

I have read Research and Markets' Privacy Policy and consent to the processing of my personal data.

We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.